Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-blind Phase 2 trial of tideglusib in adolescent and adult congenital and juvenile-onset myotonic dystrophy type 1
2016-000067-16Phase 2Completed
- Sponsor
- AMO Pharma Limited
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind trial of tideglusib in myotonic dystrophy type 1 (DM1) (2 arms), sponsored by AMO Pharma Limited. Primary endpoint: Incidence of adverse events. Started May 2016; status: completed.
02
Drugs
tideglusib
03
Conditions
myotonic dystrophy type 1 (DM1)
Beyond the preview
Go deeper on 2016-000067-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000067-16.